Pharmaceutical company Breckenridge Pharmaceutical Inc revealed on Monday the receipt of US Food and Drug Administration final approval for its Abbreviated New Drug Application for Rivastigmine Transdermal System in 4.6mg/24 hours, 9.5mg/24 hours and 13.3mg/24 hours strengths.
The Rivastigmine Transdermal System in 4.6mg/24 hours, 9.5mg/24 hours and 13.3mg/24 hours strength is the generic for Exelon Patch by Novartis. Breckenridge plans to launch the product with immediate effect.
Rivastigmine Transdermal System was developed in collaboration with Welding GMBH & Co KG, SK Chemicals Co Ltd and Breckenridge.
For the 12 months ending 30 September 2019, the Exelon Patch and its therapeutic equivalents generated annual sales of USD161m according to industry sales data.
Oncternal Presents Clinical Data Update on Cirmtuzumab in Combination with Ibrutinib
US FDA grants approval to Meitheal Pharmaceuticals' Enoxaparin Sodium Injection
FerGene reveals positive results from Phase three nadofaragene firadenovec clinical trial
Amgen receives FDA approval for AVSOLA (infliximab-axxq) across inflammation portfolio
Gelesis raises USD84m in new capital to support commercialisation of Plenity
Veracyte Acquires Exclusive License to NanoString Diagnostics Platform